Today, the Honourable Mark Holland, Minister of Health, announced a new appointment to the Patented Medicine Prices Review Board (PMPRB). Following a merit-based selection process, Dr. Emily A. Reynen has been appointed to the Board for a five-year term.
The Government of Canada is committed to appointing highly-qualified candidates to best serve the interests of Canadians and is committed to open, transparent, and merit-based processes for selecting Governor in Council appointees. Appointees play a fundamental role in Canadian democracy as they serve on commissions, boards, Crown corporations, agencies and tribunals across the country.
Dr. Reynen is currently an intensive care physician at the Quinte Health Care Belleville General Hospital. In addition, she is an Adjunct Assistant Professor at Queen's University and serves as a member of the Canadian Agency For Drugs And Technologies in Health's (CADTH) Canadian Drug Expert Committee.
The PMPRB is an independent quasi-judicial body established by Parliament in 1987 under the Patent Act. As an arm's-length organization of the government, the PMPRB protects the interests of Canadian consumers by ensuring that the prices of patented medicines sold in Canada are not excessive.
